GSK Pledges $30 Billion Investment in US R&D and Manufacturing, Focusing on Next-Gen Biopharma and AI

GSK plc has announced a monumental commitment to invest $30 billion in its research and development (R&D) and supply chain infrastructure across the United States over the next five years. This substantial investment, revealed on September 18, 2025, underscores GSK’s dedication to advancing life sciences and solidifying its leadership in healthcare innovation within the US.

Driving Innovation with $1.2 Billion in Advanced Facilities

A significant portion of this investment, $1.2 billion, is specifically allocated to the construction of advanced manufacturing facilities and the integration of AI and advanced digital technologies. This will pave the way for new, next-generation biopharma factories and laboratories across the United States. These investments are designed to build upon GSK’s already robust innovation and manufacturing footprint, ensuring that products are developed and made in the US for US patients.

Key components of the $1.2 billion investment include:

New Biologics Flex Factory in Upper Merion, Pennsylvania: Construction is slated to begin in 2026 for an additional biologics “flex” factory. This facility will be dedicated to delivering potential best-in-class new medicines for critical areas such as respiratory diseases (COPD, asthma) and various cancers (haematological, gynaecological, lung, and other solid tumors).
AI and Advanced Digital Technology Integration: GSK plans to embed new AI and advanced digital technology capabilities across its five existing manufacturing sites in four states: Pennsylvania, North Carolina, Maryland, and Montana. This will enhance operational efficiency and accelerate scientific discovery.
Enhanced Manufacturing Capabilities: The investment will also support the development of new drug substance manufacturing capabilities, as well as new and enhanced device and auto-injector capabilities and assembly, further diversifying GSK’s production portfolio.

A Testament to Global Leadership and US-UK Collaboration

Commenting on the announcement during a State Visit, GSK CEO Emma Walmsley highlighted the shared interests between the U.K. and the United States in advancing life sciences. “This week’s State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both,” Walmsley stated. She reiterated GSK’s ongoing commitment to investing over £1.5 billion in R&D annually in the U.K. while simultaneously bolstering its US operations.

The $30 billion investment encompasses capital investments across GSK’s US supply chain, alongside increased R&D drug discovery and development, and expanded clinical trial activity. The US is projected to rank first globally for the number of studies, sites, and clinical trial participants conducted by GSK over the next five years.

Building on Existing Momentum and Job Creation

This latest commitment brings GSK’s new investments in US manufacturing to approximately $2 billion over the past 12 months. This follows the commencement of construction in October 2024 for an $800 million facility at GSK’s Marietta, Pennsylvania site, which will effectively double its size and capacity. These significant manufacturing investments are expected to create hundreds of highly skilled jobs, in addition to construction roles, adding to GSK’s already substantial US workforce of approximately 15,000 employees.

Last year, GSK’s global supply chain network successfully delivered 1.7 billion packs of medicines and over 400 million vaccine doses, contributing to its ambitious goal of positively impacting the health of 2.5 billion people by the end of 2030. This new investment reaffirms GSK’s strategic vision to lead in global health innovation through robust R&D and manufacturing capabilities.